Rheumatoid Arthritis

Rheumatoid arthritis is a chronic, systemic autoimmune disease in which immune-mediated inflammation of the synovium causes symmetric polyarthritis, typically of the small joints of the hands and feet. Persistent synovitis can erode cartilage and bone, leading to joint damage, deformity, and disability, and the disease also carries systemic and extra-articular consequences.

Definition

Rheumatoid arthritis is a chronic systemic autoimmune disorder characterised by inflammatory synovitis affecting multiple joints in a symmetric distribution, which can progress to cartilage and bone erosion, joint deformity, and functional impairment.

Scope

This entry presents rheumatoid arthritis as a clinical entity within musculoskeletal medicine: its autoimmune nature, characteristic joint pattern, pathogenic mechanisms, and epidemiology, with reference to the general evidence base. It is reference-educational and does not provide individualised treatment guidance or drug dosing.

Key concepts

• Autoimmune synovitis
• Symmetric small-joint polyarthritis
• Autoantibodies (rheumatoid factor, anti-CCP)
• Pannus formation and bone erosion
• Systemic and extra-articular involvement
• Disease-modifying treatment and the window of opportunity
• Treat-to-target concept

Mechanisms

Rheumatoid arthritis develops when a breakdown of immune tolerance — shaped by genetic susceptibility and environmental triggers such as smoking — leads to autoantibody production (including rheumatoid factor and anti-citrullinated protein antibodies) often years before symptoms. Established disease features inflammatory synovial proliferation (pannus) driven by activated immune cells and cytokines, which mediates cartilage degradation and bone erosion. Distinct molecular pathways underlie seropositive and seronegative forms, reflecting heterogeneous origins with a convergent inflammatory outcome.

Clinical relevance

Because uncontrolled inflammation drives irreversible joint damage, early recognition and the concept of a therapeutic 'window of opportunity' are emphasised in the literature. Rheumatoid arthritis is relevant to rehabilitation through its effects on joint function, pain, and disability. This entry summarises the disease for reference and does not constitute individualised medical advice.

Epidemiology

Rheumatoid arthritis affects roughly 0.5-1% of adults in many populations, occurs more often in women, and typically begins in middle age; it is among the more common chronic inflammatory autoimmune diseases.

History

Recognition of rheumatoid arthritis as a distinct systemic autoimmune disease and the elucidation of its cytokine-driven pathogenesis through the late twentieth and early twenty-first centuries reshaped both classification and management, and contemporary reviews trace the move toward early, targeted treatment.

Debates

Are seropositive and seronegative rheumatoid arthritis one disease?

Evidence that autoantibody-positive and autoantibody-negative forms may arise through divergent mechanisms raises the question of whether they should be viewed as distinct entities with a shared clinical phenotype.

Seminal works

• mcinnes-2011
• smolen-2016
• di-matteo-2023

Frequently asked questions

How does rheumatoid arthritis differ from osteoarthritis?

Rheumatoid arthritis is a systemic autoimmune disease that inflames the joint lining symmetrically and can erode bone, whereas osteoarthritis is a degenerative whole-joint disorder driven largely by mechanical and metabolic factors.

Why is early diagnosis emphasised?

Inflammation can cause irreversible joint damage, so the literature stresses early recognition and a 'window of opportunity' for controlling disease before structural harm accumulates.